Withdrawal of cerivastatin from the world market
Top Cited Papers
Open Access
- 26 September 2001
- journal article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 2 (5), 205-207
- https://doi.org/10.1186/cvm-2-5-205
Abstract
Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was 10 times more common with cerivastatin than the other five approved statins. We address three important questions raised by this withdrawal. Should we continue to approve drugs on surrogate efficacy? Are all statins interchangeable? Do the benefits outweigh the risks of statins? We conclude that decisions regarding the use of drugs should be based on direct evidence from long-term clinical outcome trials.This publication has 7 references indexed in Scilit:
- Bayer faces potential fine over cholesterol lowering drugBMJ, 2001
- The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptionsTrials, 2001
- Evolution of genetic analysis strategies in coronary heart disease: a case of unnatural selection?European Heart Journal, 2001
- Debate: The slippery slope of surrogate outcomesTrials, 2000
- Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery DiseaseCirculation, 2000
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein CholesterolThe New England Journal of Medicine, 1999
- Natural Statins and Stroke RiskCirculation, 1999